Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Radiation Therapy Oncology Group
Centre Antoine Lacassagne
GERCOR - Multidisciplinary Oncology Cooperative Group
Eastern Cooperative Oncology Group
University of Chicago
Rutgers, The State University of New Jersey
University of Texas Southwestern Medical Center
University of Texas Southwestern Medical Center
National Cancer Institute (NCI)
Fox Chase Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Washington
National Cancer Institute (NCI)
Fox Chase Cancer Center